1. "Eileen O'Reilly"
  2. "Meeting abstract"
Formats
  1. Meeting Abstract (313)
Groups
  1. Center for Pancreatic Cancer Research (313)
  2. Department of Medicine (313)
  3. Gastrointestinal Oncology Service (313)
  4. Solid Tumor Oncology Division (313)
  5. Epidemiology and Biostatistics (69)
  6. Biostatistics Service (57)

More Groups

People
  1. Eileen O'Reilly (313)
  2. Kenneth Yu (60)
  3. Ghassan Abou-Alfa (52)
  4. Maeve Lowery (49)
  5. David Kelsen (44)
  6. Marinela Capanu (42)

More People

Years
  1. 2024 (7)
  2. 2023 (39)
  3. 2022 (29)
  4. 2021 (25)
  5. 2020 (35)
  6. 2019 (33)

More Years

Publications
  1. Journal of Clinical Oncology (212)
  2. Annals of Oncology (31)
  3. Cancer Research (12)
  4. Annals of Surgical Oncology (10)
  5. International Journal of Radiation Oncology, Biology, Physics (9)
  6. Oncology Research and Treatment (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (212)
  2. Oxford University Press (31)
  3. American Association for Cancer Research (16)
  4. Elsevier Inc. (14)
  5. Springer (10)
  6. Lippincott Williams & Wilkins (8)

More Publishers

Results (313)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Meeting Abstract

    Hall, M. J.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies
    Meeting Abstract

    Bendell, J. C.; Manji, G. A.; Pant, S.; Lai, D. W.; Colabella, J.; Berry, W.; Paoloni, M. C.; Grossman, W. J.; O'Reilly, E. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized phase II trial of pazopanib versus placebo in patients (Pts) with progressive carcinoid tumors (CARC) (Alliance A021202)
    Meeting Abstract

    Bergsland, E.; Mahoney, M.; Asmis, T.; Hal, N.; Kumthekar, P.; Maitland, M.; Neidzwiecki, D.; Nixon, A.; O'Reilly, E.; Schwartz, L.; more...
    Pancreas (2020)

    Fulltext@MSK | Save
  • PD-1 blockade in advanced adrenocortical carcinoma
    Meeting Abstract

    Raj, N.; Zheng, Y.; Kelly, V.; Katz, S.; Chou, J.; Do, R.; Capanu, M.; Zamarin, D.; Saltz, L.; Ariyan, C.; more...
    Pancreas (2020)

    Fulltext@MSK | Save
  • POLO: Efficacy and health-related quality of life (HRQOL) with maintenance olaparib following first-line platinum-based chemotherapy (PBC) in patients (PTS) with a germline BRCA mutation and metastatic pancreatic cancer (MPC)
    Meeting Abstract

    Reinacher-Schick, A. C.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Prognostic value of the Memorial Sloan Kettering (MSK) prognostic score (MPS) in pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Lebenthal, J.; Zheng, J. T.; Glare, P. A.; O'Reilly, E. M.; Epstein, A. S.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Improving health outcomes in pancreatic cancer using animated pancreas patient (APP) visual formats of learning: A National Pancreas Foundation (NPF) patient education initiative
    Meeting Abstract

    Munigala, S.; O'Reilly, E. M.; Alsante, M.; Holt, J. M.; Ko, A. H.; Gelrud, A.
    Pancreas (2019)

    Fulltext@MSK | Save
  • Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients with a germline BRCA mutation and metastatic pancreatic vancer (mPC): Phase III POLO trial
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Pancreas (2019)

    Fulltext@MSK | Save
  • APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) versus gemcitabine (G) for surgically resected pancreatic adenocarcinoma
    Meeting Abstract

    Ko, A.; Reni, M.; Riess, H.; Pelzer, U.; O'Reilly, E. M.; Winter, J.; Oh, D. Y.; Li, C. P.; Tortora, G.; Chang, H. M.; more...
    Pancreas (2019)

    Fulltext@MSK | Save